SUNLIGHT Trial Shows Bevacizumab with Trifluridine/Tipiracil Improves Survival and Quality of Life in Refractory mCRC

A recent discussion among medical experts highlighted the findings of the SUNLIGHT trial, which demonstrated that adding bevacizumab to trifluridine/tipiracil significantly improves overall survival (OS) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer (mCRC). The trial also revealed that this combination therapy delays the time to definitive deterioration in quality of life (QoL), a factor deemed critical for patient counseling in advanced treatment settings.

The panelists emphasized that patients receiving third-line or later treatments often prioritize both extending survival and maintaining their quality of life. The SUNLIGHT trial’s data suggest that the addition of bevacizumab provides measurable efficacy improvements without causing substantial declines in patient well-being. These findings are considered particularly relevant for guiding treatment decisions, as they offer evidence supporting a balance between therapeutic benefits and QoL preservation.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: August 7, 2025

Related posts:

Biotech Companies Advance Drug Development, Clinical Trials, and Portfolio Expansion. Prabhakaran Nair Appointed Global Chief Manufacturing Officer at Cipla Effective July 2025 Piramal Pharma Expands Biologics Manufacturing with Focus on Integrated Drug Development 3D-Printed Tumor Models Developed to Enhance Surgical Imaging Precision

Author

Mark Chiang